Samir Germanwala, DO
Cardiovascular Disease · Longview, TXNPI 1043287816
Payments from drug & device makers
Across 1,477 payments — averaging $97.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$70K
- Johnson & Johnson$31K
- Abbott$17K
- W. L. Gore & Associates, Inc.$6K
- AstraZeneca$4K
- Edwards Lifesciences$3K
- plus $14K from 32 others
What the payments were for
- Consulting fees$6,6965%
- Speaking & faculty fees$97,36568%
- Travel & lodging$7,1725%
- Food & beverage$32,54423%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 186 | $69,715 |
| Johnson & Johnson(2 entities) | 62 | $30,537 |
| Abbott | 249 | $17,226 |
| W. L. Gore & Associates, Inc. | 217 | $5,536 |
| AstraZeneca | 13 | $3,985 |
| Edwards Lifesciences | 108 | $3,275 |
| Bard Peripheral Vascular, Inc. | 103 | $2,606 |
| Biosense Webster, Inc. | 119 | $2,142 |
| Penumbra, Inc. | 12 | $1,747 |
| Boston Scientific | 88 | $1,370 |
| Novartis | 95 | $1,164 |
| Shockwave Medical, Inc | 41 | $945 |
| Philips North America LLC | 35 | $660 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 28 | $380 |
| Merck | 22 | $373 |
| Cardiovascular Systems Inc. | 13 | $299 |
| E.r. Squibb & Sons, L.L.C. | 16 | $281 |
| Inari Medical, Inc. | 11 | $274 |
| Stryker | 10 | $200 |
| Amgen | 14 | $192 |
| Alnylam Pharmaceuticals Inc. | 2 | $161 |
| Abiomed | 6 | $129 |
| Cvrx, Inc. | 3 | $116 |
| Itamar Medical Inc | 3 | $103 |
| Pfizer | 4 | $65 |
| Boehringer Ingelheim | 4 | $60 |
| Novo Nordisk | 2 | $36 |
| Scpharmaceuticals Inc. | 1 | $33 |
| Heartflow, Inc. | 1 | $28 |
| Bayer | 1 | $24 |
| BD | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Teleflex LLC | 1 | $15 |
| Acist Medical Systems, Inc. | 1 | $14 |
| Cook Medical LLC | 1 | $14 |
| Chiesi USA, Inc. | 1 | $14 |
| Terumo Medical Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$56,237
- XARELTO$29,682
- HawkOne$10,739
- AVEIR$3,923
- BRILINTA$3,850
- Assurity Pacemaker$3,264
- Fortify Assura, Ellipse ICD$2,396
- Indigo System$1,134
- Mitra Clip system$717
- Quadra Assura CRT Defibrillator$576
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$448
- Durata Defibrillation ICD Lead$405
- Indigo$382
- Edwards SAPIEN 3 Transcatheter Heart Valve$347
- SAPIEN 3 Ultra RESILIA$345
- Confirm Rx$334
- MitraClip$306
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$216
- Tendril Pacing Lead$143
- CardioMEMS HF System$141
How this compares
$143,787 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 283 | $203,135 |
| XareltoRivaroxaban | 169 | $163,462 |
| EntrestoSacubitril/Valsartan | 169 | $127,385 |
| Repatha SureclickEvolocumab | 81 | $57,347 |
| MultaqDronedarone Hcl | 12 | $21,303 |
| JardianceEmpagliflozin | 25 | $20,943 |
| FarxigaDapagliflozin Propanediol | 24 | $14,431 |
| ClopidogrelClopidogrel Bisulfate | 998 | $8,297 |
| Metoprolol Succinate | 350 | $4,252 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 17 | $3,379 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 89 | $2,106 |
| Carvedilol | 170 | $1,120 |
| Losartan Potassium | 128 | $1,070 |
| Nebivolol Hcl | 20 | $964 |
| Amlodipine Besylate | 141 | $917 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $65 | $203,135283 claims |
| Johnson & JohnsonXarelto | $30,537 | $163,462169 claims |
| NovartisEntresto | $1,164 | $127,385169 claims |
| Sanofi-aventis U.S. LLCMultaq | $17 | $21,30312 claims |
| Boehringer IngelheimJardiance | $60 | $20,94325 claims |
| AstraZenecaFarxiga | $3,985 | $14,43124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Longview
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.